ArriVent BioPharma logo

ArriVent BioPharma

AVBP | NASDAQ
Chart Builder DCF Calculator
$11.56
-$1.45 (-11.15%)
At close: Nov 16, 2026, 4:00 PM ET
$11.56
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-11.15%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
44.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #396/1021 (Top 39%)

Key Statistics

Market Data

Market Cap $597.92M
1D Range
11.55 13.14
52W Range
11.55 34.74

Valuation (TTM)

PE -3.16
PB 1.52
EV/EBITDA -1.19

Valuation (NTM)

Forward PE N/A
Forward PEG 0.31
Price Target $27.00
Loading financial charts...

Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancer...

Sector Healthcare
Industry Biotechnology
Employees 77
IPO Date Jan 26, 2024
Fiscal Year January - December

Latest News

ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low

1 month ago · benzinga.com

ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

1 month ago · globenewswire.com

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
ArriVent BioPharma Reports Second Quarter 2026 Financial Results

3 months ago · globenewswire.com

ArriVent BioPharma Reports Second Quarter 2026 Financial Results
ArriVent BioPharma Reports First Quarter 2026 Financial Results

6 months ago · globenewswire.com

ArriVent BioPharma Reports First Quarter 2026 Financial Results
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

7 months ago · zacks.com

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

7 months ago · zacks.com

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

8 months ago · zacks.com

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?

8 months ago · zacks.com

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

8 months ago · zacks.com

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
ArriVent BioPharma Reports Full Year 2025 Financial Results

9 months ago · globenewswire.com

ArriVent BioPharma Reports Full Year 2025 Financial Results

Earnings

Latest Earnings
Nov 9, 2026
EPS
-$0.81
Beat +22.86%
REV
$5M
Beat +525.00%
Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
8
Consensus
Buy
Price Target
$27.00
Upside
+133.56%
Buy (8)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.